Katy Stephenson, MD, MPH Profile picture
May 19, 2021 14 tweets 5 min read Read on X
The recent change in @CDCgov policy regarding masking has prompted a lot of people to ask: do #COVID19 #vaccines block transmission of the virus to others? Here is a 🧵using slides my colleagues and I put together recently. @DrJRMarcelin @ElizabethRBrow2
Slides made by me (Harvard), Audrey Pettifor (UNC), Jasmine Marcelin (UNMC), and Holly Janes and Elizabeth Brown at the Hutch.
It seems like there is new data every day, so apologies if our slides are already missing something. But here is a summary of some good observational studies on the topic.
Same with the trial data - constantly evolving. Here's a sample. VE means vaccine efficacy
This question comes up a lot - a little data showing that asymptomatic infections can have a decent amount of viral shedding
Might be simple for some, but it helps to remember how easily observational studies can be misinterpreted
Another common mistake in observational studies
Measuring viral kinetics is extremely challenging - the frequency of testing is a huge factor in accuracy
This is may be the most relevant point recently. We still don't know very much about transmission events following breakthrough infections.
How is this all relevant to the masking policies? The point here is that we know that vaccines block asymptomatic infection, at least partially. But we don't know a lot about how much forward transmission can occur in the setting of breakthrough infections.
This data may not always be so important! If everyone is vaccinated, then it's not a big deal. We're all protected against symptomatic disease. And if there's extremely low amounts of virus circulating, it also may not be a big deal.
When this data really matters is when there is partial vaccination and moderate amounts of circulating virus. That's when we really need to accurately understand the risk of transmission following breakthrough infections. And we don't have that data yet.
This study reminds me of the above limitation. They looked at incidence rates among non-vaccinated pts at the same time that general incidence rates were dropping. Of course vaccines are amazing, but not sure how robust the findings are here.@walidgellad
nytimes.com/2021/05/19/hea…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Katy Stephenson, MD, MPH

Katy Stephenson, MD, MPH Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @k_stephensonMD

Aug 5, 2022
New pre-print on Paxlovid rebound from our group @BIDMC_CVVRTrial, along with @sabeti_lab, Amy Barczak @ragoninstitute and @mispri2.

We enrolled 36 people with SARS-CoV-2 (11 on Paxlovid) and did PCR every day for 2+ weeks. Here’s what we found… (1/8)
medrxiv.org/content/10.110…
One person out of 25 in the untreated group had viral rebound (4%), defined as at least 2 negative PCRs followed by at least 2 positives. 3 people out of 11 who took Paxlovid had rebound (27%). Those that rebounded after Paxlovid looked similar to an acute infection (2/8)
(abrupt rise to a high level of virus, with 6-12 days to clear). The single case of viral rebound without treatment was more like a viral “blip.”

For people who didn’t rebound, Paxlovid significantly reduced the # of days positive – from 7 days to 3.5 days. But when (3/8)
Read 9 tweets
Feb 3, 2022
I gave a talk this morning about #Omicron with @PaulSaxMD @SanjatKanjilal & Dr. Ruanne Barnabas. We covered a lot of science but our bottom line was always the same: we need to increase access to diagnostics, treatments & vaccines to truly control COVID-19. 🧵and slides... 1/10
It's only been a year since we rolled out our vaccines, but since then we have administered >10 billion doses and probably prevented >1 million deaths in US alone. But inequity in global vaccination persists. 2/10
Omicron has created a challenge for our vaccines because of mutations in its spike protein, and this has led to reduced neutralizing antibody activity following a primary vaccine series. This has translated to increased breakthrough infections in real world studies. 3/10
Read 11 tweets
Aug 7, 2021
Obviously it's good news that J&J vaccine is holding up against delta in data from South Africa. But the only reason we have that data is bc some insanely resourceful scientist heroes in SA scratched out 500K doses from thin air to protect their health care workers when ..
there were no COVID-19 vaccines in the entire country. Now we sit back in the US and watch delta surges burn through country after country and just lap up the data to help reassure us about the doses we already got! What's amazing about this study, what we really
should be talking about is how @LindaGailBekker Glenda Gray @nigegarrett had the guts to leverage research to vaccinate a half million health care workers who are now out there, protected, fighting to save countless unvaccinated South Africans through an incredibly chaotic time,
Read 4 tweets
Jul 8, 2021
We just released data on the durability of immune responses following the J&J #COVID19 #vaccine, including responses against #delta. The paper is in press @NEJM and this is the pre-print. To help explain the data, here’s a 🧵... 1/12 medrxiv.org/content/10.110…
Dan Barouch, myself and partners started running a 25 person study @BIDMC_CVVRTrial in July 2020 as part of the phase 1 J&J vaccine program. The study tests 1 dose vs. 2 doses (as well as high doses) against placebo. This study looks at immune responses – not efficacy. 2/12
First, a look back to some earlier data. Something not appreciated by general public from early data – there is no difference in immune responses between 1 vs. 2 doses at almost any time point we looked at. Importantly, this is when boost is given 2 months after first shot. 3/12 Image
Read 12 tweets
Mar 9, 2021
Thanks to @Anna_Rothschild and @FiveThirtyEight for having me on PODCAST-19 to discuss the future of #COVID19 #vaccines as we enter new phases of this pandemic. What an honor to be joined by @JuliaLMarcus! My main point is that I think there are ... 1/5
fivethirtyeight.com/features/turni…
two types of vaccines. First there are 'pandemic' vaccines, which is what we have now - excellent at preventing hospitalizations and deaths and most useful for decompressing our health care infrastructure and reducing mortality in the most vulnerable. These vaccines will ... 2/5
have the biggest impact on returning to normal, so to speak, where schools, restaurants and workplaces can open up again. The second type of vaccines are 'maintenance' vaccines which are going to come as boosters or 2.0 versions optimized for new variants....3/5
Read 5 tweets
Nov 17, 2020
Hi friends! Today's news about the NIH-Moderna #COVID19 #vaccine is astonishingly good. I've never seen my colleagues - weathered, skeptical professor types - so giddy and delighted and surprised. Here's a thread about what it means (and doesn't): 🧵 1/n
There are caveats and I will get to them (wear a mask!), but for a moment let's look at the amazing numbers they reported: there were 95 cases of COVID-19 so far and *90* of those cases were in the group that got the fake (placebo) group. Only 5 cases were in the vaccine ... 2/14
group. The vaccine also seemed to protect against severe disease. There were 11 cases of severe COVID-19 in the placebo group and 0 cases in the vaccine group. 🤩 Wow!
So now, other things to know: ... 3/14
Read 14 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(